

Please type a plus sign (+) inside this box →




PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission **4 + REFS.**

Application Number **10/801,729**

Filing Date **March 15, 2004**

First Named Inventor **KAO, PETER N.**

Group Art Unit **1614**

Examiner Name

Attorney Docket Number **STAN-352**

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Reply
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Documents
- ☐ Response to Missing Parts/
Incomplete Application
- ☐ Response to Missing Parts
under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers
(for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a
Provisional Application
- ☐ Power of Attorney, Revocation
Change of Correspondence
Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)

- ☐ After Allowance Communication
to Group
- ☐ Appeal Communication to Board
of Appeals and Interferences
- ☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please
identify below):
 - 1. Form PTO/SB/08A
 - 2. Copies of cited references
 - 3. Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent
(Reg. No.)

PAMELA J. SHERWOOD, 36.677
BOZICEVIC, FIELD & FRANCIS, LLP

Signature

Date


November 18, 2004

EXPRESS MAIL LABEL NO. EV519866935US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail No. EV519866935US

INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 	Attorney Docket	STAN-352
	First Named Inventor	KAO, PETER N.
	Application Number	10/801,729
	Confirmation No.	1829
	Filing Date	March 15, 2004
	Group Art Unit	1614
	Examiner Name	
	Title:	"USE OF ANTIPROLIFERATIVE AGENTS IN THE TREATMENT AND PREVENTION OF PULMONARY PROLIFERATIVE VASCULAR DISEASES"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-352 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: November 18, 2004

By: 
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Substitute for form 1449A/PTO		NOV 18 2004		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/801,729
				Filing Date	March 15, 2004
				First Named Inventor	KAO, PETER N.
				Art Unit	1614
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	STAN-352

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ³ (if known)				
		US- 5,968,983		October 19, 1999	Kaesemeyer	
		US- 6,147,109		November 14, 2000	Liao, et al.	
		US- 6,425,881		July 30, 2002	Kaesemeyer	

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BERGER, R, et al., ALTERED ARTERIAL EXPRESION PATTERNS OF INDUCIBLE AND ENDOTHELIAL NITRIC OXIDE SYNTHASE IN PULMONARY PLEXOGENIC ARTERIOPATHY CASUED BY CONGENITAL HEART DISEASE, (2001), Am. J. Respir. Crit. Care Med., 163:1493-1499	
		BUSTOS, C. et al., HMG-COA REDUCTASE INHIBITION BY ATORVASTATIN REDUCES NEOINTIMAL INFLAMMATION IN A RABBIT MODEL OF ATHEROSCLEROSIS, (1998), J. Am. Coll. Cardiol., 32:2057-2064	
		DENG, Z. et al., FAMILIAL PRIMARY PULMONARY HYPERTENSION (GENE PPH1) IS CAUSED BY MUTATIONS IN THE BONE MORPHOGENETIC PROTEIN RECEPTOR-II GENE, (2000), Am. J. Hum. Genet., 67:737-744	
		INDOLFI, C. et al., EFFECTS OF HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR SIMVASTATIN ON SMOOTH MUSCLE CELL PROLIFERATION IN VITRO AND NEOINTIMAL FORMATION IN VIVO AFTER VASCULAR INJURY, (2000), J. Am. Coll. Cardiol., 35: 214-221	
		KOBASHIGAWA, J.A. et al., EFFECT OF PRAVASTATIN ON OUTCOMES AFTER CARDIAC TRANSPLANTATION, (1995), N. Engl. J. Med., 333:621-627	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/801,729	
			Filing Date	March 15, 2004	
			First Named Inventor	KAO, PETER N.	
			Group Art Unit	1614	
Sheet	2	of	2	Examiner Name	
				Attorney Docket Number	STAN-352

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		KOH, K.K., EFFECTS OF STATINS ON VASCULAR WALL: VASOMOTOR FUNCTION, INFLAMMATION, AND PLAQUE STABILITY, (2000), Cardiovascular Res., 47: 648-657	
		KWAK, B. et al., STATINS AS A NEWLY RECOGNIZED TYPE OF IMMUNOMODULATOR, (2000), Nat. Med., 6:1399-402	
		LAUFS, U. et al., INHIBITION OF 3-HYDOXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE BLOCKS HYPOXIA-MEDIATED DOWN-REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE, (1997), J. Biol. Chem., 272: 31725-31729	
		LAUFS, U. et al., 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS ATTENUATE VASCULAR SMOOTH MUSCLE PROLIFERATION BY PREVENTING RHO GTPASE-INDUCED DOWN-REGULATION OF P27 ^{KIP1} , (1999), J. Biol. Chem., 274: 21926-21931	
		MACHADO, R.D. et al., BMPR2 HAPLOINSUFFICIENCY AS THE INHERITED MOLECULAR MECHANISM FOR PRIMARY PULMONARY HYPERTENSION, (2000), Am. J. Hum. Genet., 68:92-102	
		MARON, D.J., et al., CURRENT PERSPECTIVES ON STATINS, (2000), Circulation, 101:207-13	
		NEWMAN, J.H., et al., MUTATION IN THE GENE FOR BONE MORPHOGENETIC PROTEIN RECEPTOR II AS A CAUSE OF PRIMARY PULMONARY HYPERTENSION IN A LARGE KINDRED, (2001), New Engl. J. Med., 345:319-324	
		WEITZ-SCHMIDT, G. et al., STATINS SELECTIVELY INHIBIT LEUKOCYTE FUNCTION ANTIGEN-1 BY BINDING TO A NOVEL REGULATORY INTEGRIN SITE, (2001), Nat. Med., 7:687-92	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.